share_log

Earnings Troubles May Signal Larger Issues for Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) Shareholders

Earnings Troubles May Signal Larger Issues for Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) Shareholders

收益問題可能預示着杭州中泰低溫科技(SZSE:300435)股東面臨更大問題
Simply Wall St ·  10/31 07:37

Hangzhou Zhongtai Cryogenic Technology Corporation's (SZSE:300435) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.

中泰股份(SZSE:300435)最近的業績報告弱勢,並未引起股票大幅波動。然而,我們認爲投資者應該注意一些潛在的擔憂因素。

big
SZSE:300435 Earnings and Revenue History October 30th 2024
SZSE:300435盈利和營業收入歷史數據爲2024年10月30日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Hangzhou Zhongtai Cryogenic Technology's profit received a boost of CN¥29m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Hangzhou Zhongtai Cryogenic Technology doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據顯示,中泰股份的利潤在過去一年中因飛凡項目獲得了2900萬人民幣的提振。我們不能否認,更高的利潤通常讓我們感到樂觀,但我們更希望利潤能夠持續下去。當我們分析了成千上萬家上市公司的數據後,我們發現一年中由飛凡項目帶來的提振往往不會在下一年重複。畢竟,這正是會計術語所暗示的。如果中泰股份未看到該貢獻在下一年重複,那麼其他條件相同,我們預計其利潤將在當前年度下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Hangzhou Zhongtai Cryogenic Technology's Profit Performance

我們對中泰股份的利潤表現的看法

We'd posit that Hangzhou Zhongtai Cryogenic Technology's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Hangzhou Zhongtai Cryogenic Technology's true underlying earnings power is actually less than its statutory profit. Nonetheless, it's still worth noting that its earnings per share have grown at 23% over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 1 warning sign for Hangzhou Zhongtai Cryogenic Technology you should be aware of.

我們認爲中泰股份的法定盈利並不能清晰反映持續生產力,因爲有大筆飛凡項目。因此,據我們看來,中泰股份的真正基礎盈利能力實際上可能低於其法定利潤。儘管如此,仍值得注意的是,其每股收益在過去三年中增長了23%。當然,在分析其盈利方面我們僅僅是粗略了解了一部分;人們也可以考慮邊際、預測增長和投資回報率等其他因素。考慮到這一點,除非我們對風險有深入了解,否則我們不會考慮投資股票。案例證明:我們發現了中泰股份的1個警示信號,您應該注意。

This note has only looked at a single factor that sheds light on the nature of Hangzhou Zhongtai Cryogenic Technology's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這篇筆記只研究了一個能揭示中泰股份利潤性質的因素。但有許多其他方法可以了解一家公司。例如,許多人認爲高股本回報率是有利的商業經濟指標,而另一些人喜歡「跟隨資金」並尋找內部人員買入的股票。因此,您可能希望查看這批自豪具有高股本回報率的公司,或者這份具有高內部所有權股票的列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論